Oric Pharmaceuticals (ORIC) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ORIC Oric Pharmaceuticals

Watchlist

8.360
+0.090+1.09%

Close Feb 14 16:00 ET

8.310
-0.050-0.60%

Post 20:01 ET

589.94MMarket Cap-4.59P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Buy Rating on Oric Pharmaceuticals: Capitalizing on Prostate Cancer Treatment Advances
TipRanksFeb 14 10:25 ET · Ratings
Wedbush Remains a Buy on Oric Pharmaceuticals (ORIC)
TipRanksFeb 14 08:45 ET · Ratings
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC) and Biogen (BIIB)
TipRanksFeb 12 08:32 ET · Ratings
Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $15
Moomoo NewsFeb 12 08:31 ET · Ratings
J.P. Morgan Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating
Moomoo NewsFeb 11 10:32 ET · Ratings
A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $17 to $21
Moomoo NewsFeb 11 08:00 ET · Ratings

Comments

Stock_Drift

Jul 16, 2024 18:19

📊⚡️📊

$Oric Pharmaceuticals (ORIC.US)$ $BAYER AG (BAYRY.US)$ $Johnson & Johnson (JNJ.US)$

Moomoo AI

Oct 11, 2023 14:38

Despite a promising cash runway, ORIC Pharmaceuticals' cash burn relative to its market cap may pose future risks. If new shares are issued to fund operations, shareholders could face costly dilution. The cash burn is not a major concern currently, but shareholders need to pay attention.